The result consolidates Jemperli’s position in front-line endometrial cancer therapy as it faces potential competition from MSD’s Keytruda (pembrolizumab), which was also shown to extend PFS ...

Jemperli's earlier indications across endometrial cancer and dMMR solid tumours have generated modest revenues, coming in at £36 million ($46 million) in the first six months of this year and ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

GSK acquired both Jemperli (co-developed with AnaptysBio) and Zejula through its $5.31 billion acquisition of Tesaro in 2019. After the FDA’s accelerated approval in 2021 for patients with mismatch ...

Immunotherapies approved for endometrial cancer include MSD’s Keytruda (pembrolizumab) AstraZeneca’s Imfinzi (durvalumab), and Jemperli (dostarlimab). There are no currentlyapproved ADCs for ...

ASCO 2025: GSK’s Jemperli fails to show OS benefit in 1L advanced ovarian cancer To expand Jemperli’s success beyond endometrial cancer · Clinical Trials Arena GlobalData Healthcare ...

In this video, Susana M. Campos, MD, MPH, discusses new research on adding metformin to letrozole/abemaciclib for the treatment of estrogen receptor-positive, recurrent endometrial cancer.The data ...

More information: Dana M. Chase et al, Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer ...

For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and maintenance of quality of life.

While common symptomatology of endometrial cancer leads to early diagnosis and favorable 5-year survival in most cases, ... News GSK's Cancer Drug Jemperli Gets File Acceptance From FDA; ...

Background: Immune checkpoint inhibitors (ICIs) in combination with chemotherapy have become a standard first-line treatment for advanced endometrial cancer with increased response rate and ...